Assertio Therapeutics Inc Cash Flow Conversion Efficiency
Assertio Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has a cash flow conversion efficiency ratio of 0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.56 Million) by net assets ($75.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Assertio Therapeutics Inc (1996–2025)
Cash flow conversion efficiency of Assertio Therapeutics Inc from 1996 to 2025. This chart illustrates how Assertio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Assertio Therapeutics Inc stock price for real-time trading data and today's change.
Assertio Therapeutics Inc Cash Flow Conversion Ratio Explained
Assertio Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Assertio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assertio Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Assertio Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fu Yu Property Co Ltd
TWO:4907
|
0.079x |
|
TIL Limited
NSE:TIL
|
-0.193x |
|
BurTech Acquisition Corp
NASDAQ:BRKH
|
-0.023x |
|
Koenig & Bauer AG
XETRA:SKB
|
0.098x |
|
Melar Acquisition Corp. I Unit
NASDAQ:MACIU
|
-0.001x |
|
Wendell Industrial Co. Ltd
TWO:6761
|
0.017x |
|
Lionsgate Studios Holding Corp.
NYSE:LION
|
-0.051x |
|
AI Infrastructure Acquisition Corp.
NYSE:AIIA
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Assertio Therapeutics Inc from 1996 to 2025. Review Assertio Therapeutics Inc (ASRT) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.95 Million | $-28.18 Million | -0.300x | -237.53% |
| 2024-12-31 | $121.08 Million | $26.41 Million | 0.218x | -39.32% |
| 2023-12-31 | $138.00 Million | $49.60 Million | 0.359x | +3.23% |
| 2022-12-31 | $225.72 Million | $78.60 Million | 0.348x | +545.68% |
| 2021-12-31 | $102.41 Million | $5.52 Million | 0.054x | +104.57% |
| 2020-12-31 | $55.51 Million | $-65.57 Million | -1.181x | -175.67% |
| 2019-12-31 | $57.96 Million | $90.47 Million | 1.561x | +374.44% |
| 2018-12-31 | $220.34 Million | $72.50 Million | 0.329x | -10.28% |
| 2017-12-31 | $169.51 Million | $62.17 Million | 0.367x | +40.42% |
| 2016-12-31 | $250.79 Million | $65.50 Million | 0.261x | -42.81% |
| 2015-12-31 | $315.06 Million | $143.89 Million | 0.457x | +397.67% |
| 2014-12-31 | $364.45 Million | $-55.92 Million | -0.153x | -316.15% |
| 2013-12-31 | $137.42 Million | $9.75 Million | 0.071x | +119.23% |
| 2012-12-31 | $83.94 Million | $-30.98 Million | -0.369x | -167.82% |
| 2011-12-31 | $105.92 Million | $57.65 Million | 0.544x | +628.20% |
| 2010-12-31 | $23.11 Million | $-2.38 Million | -0.103x | -188.17% |
| 2009-12-31 | $15.73 Million | $1.84 Million | 0.117x | +15.63% |
| 2008-12-31 | $33.15 Million | $3.35 Million | 0.101x | -68.62% |
| 2007-12-31 | $45.52 Million | $14.66 Million | 0.322x | -68.27% |
| 2006-12-31 | $-27.29 Million | $-27.70 Million | 1.015x | -76.18% |
| 2005-12-31 | $6.76 Million | $28.82 Million | 4.262x | +253.93% |
| 2004-12-31 | $8.40 Million | $-23.27 Million | -2.769x | -188.82% |
| 2003-12-31 | $34.58 Million | $-33.15 Million | -0.959x | -238.57% |
| 2002-12-31 | $-6.41 Million | $-4.44 Million | 0.692x | -91.76% |
| 2001-12-31 | $-1.48 Million | $-12.40 Million | 8.393x | +678.64% |
| 2000-12-31 | $4.59 Million | $-6.65 Million | -1.451x | -238.96% |
| 1999-12-31 | $9.22 Million | $-3.94 Million | -0.428x | -57.48% |
| 1998-12-31 | $9.20 Million | $-2.50 Million | -0.272x | -1.28% |
| 1997-12-31 | $4.10 Million | $-1.10 Million | -0.268x | -126.83% |
| 1996-12-31 | $-400.00K | $-400.00K | 1.000x | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more